Notable Labs, Ltd. NTBL
At closeOct 22, 2024, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 2.39M
- Revenue (ttm)
- 313.00K
- EPS (ttm)
- -1.09
- Shares out
- 9.66M
- P/E ratio
- -0.23
- Forward P/E
- -0.07
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 1.93M
- Avg volume
- 2.59M
- Open
- 0.298
- Previous close
- 0.2479
- Day's range
- 0.2396 – 0.3055
- 52-week range
- 0.10 – 4.24
- Analysts
- Buy
- Price target
- 9.00 (+3530.5%)
- Earnings date
- Nov 12, 2024
Key statistics
- Enterprise value
- -172.88K
- PEG ratio
- 0.00
- Price / sales
- 7.65
- Price / book
- 0.33
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.46M
- Total cash
- 4.09M
- Total debt
- 1.79M
- Return on equity
- 0.00%
- Short % of float
- 8.05%
- 50-day average
- 0.407452
- 200-day average
- 0.866469
Analyst view
Consensus: buy
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2024
Expected Nov 12, 2024. Consensus EPS estimate -0.68.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 20, 2024 | JMP Securities | down | Market Outperform | Market Perform |
| May 16, 2024 | Chardan Capital | main | Buy | Buy |
| Apr 15, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Apr 15, 2024 | Chardan Capital | main | Buy | Buy |
About Notable Labs, Ltd.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California. On October 13, 2024, Notable Labs, Ltd. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- notablelabs.com
News
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket 
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket 
Notable Labs to Present Data on September 4th at SOHO 2024 
Notable Labs Announces CEO Transition 
Bears are Losing Control Over Notable Labs (NTBL), Here's Why It's a 'Buy' Now 
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock? 
Notable Labs Reports 2023 Financial Results and Provides a Business Update 
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Your note
Sign in to keep a note on NTBL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BACKENROTH SAMUEL | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 30, 2023 | 525,000 |
| BOCK THOMAS A. M.D. | Chief Executive Officer | Stock Award(Grant) | May 7, 2024 | 400,000 |
| DUBIN THOMAS I.H. | Director | Stock Award(Grant) | May 7, 2024 | 40,247 |
| FEINBERG PETER | Director | Stock Award(Grant) | May 7, 2024 | 40,247 |
| FR CAPITAL HOLDINGS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 1, 2024 | 0 |
| GALEN MICHELE | Director | Stock Award(Grant) | May 7, 2024 | 40,247 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Industry Ventures, L.l.c. | 2.12% | 204,424 | 50.68K | Jun 29, 2024 |
| Founders Fund V Management, LLC | 1.22% | 117,924 | 29.23K | Jun 29, 2024 |
| Geode Capital Management, LLC | 0.31% | 29,620 | 7.34K | Jun 29, 2024 |
| Virtu Financial LLC | 0.23% | 21,946 | 5.44K | Jun 29, 2024 |
| Mariner, LLC | 0.23% | 22,003 | 5.45K | Jun 29, 2024 |
| Oppenheimer & Company Inc. | 0.21% | 20,000 | 4.96K | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.29% | 28,016 | 6.95K | Aug 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 1,153 | 285 | Aug 30, 2024 |